HEPA
Hepion Pharmaceuticals
HEPA
HEPA
Delisted
HEPA was delisted on the 12th of May, 2025.
26 hedge funds and large institutions have $2.2M invested in Hepion Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 1 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
39% less capital invested
Capital invested by funds: $3.61M → $2.2M (-$1.41M)
Holders
26
Holding in Top 10
–
Calls
$52K
Puts
$1K
Top Buyers
| 1 | +$34.5K | |
| 2 | +$19K | |
| 3 | +$5.66K | |
| 4 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
+$5.48K |
| 5 |
Renaissance Technologies
New York
|
+$4.21K |
Top Sellers
| 1 | -$20.7K | |
| 2 | -$20.7K | |
| 3 | -$14.2K | |
| 4 |
VF
Virtu Financial
New York
|
-$13.4K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$5.79K |